ATE412895T1 - Verfahren zur untersuchung der wirkung eines angiogenese-hemmers unter vermittlung durch hemmung der integrin-expression - Google Patents

Verfahren zur untersuchung der wirkung eines angiogenese-hemmers unter vermittlung durch hemmung der integrin-expression

Info

Publication number
ATE412895T1
ATE412895T1 AT06013455T AT06013455T ATE412895T1 AT E412895 T1 ATE412895 T1 AT E412895T1 AT 06013455 T AT06013455 T AT 06013455T AT 06013455 T AT06013455 T AT 06013455T AT E412895 T1 ATE412895 T1 AT E412895T1
Authority
AT
Austria
Prior art keywords
integrin expression
studying
inhibition
effect
angiogenesis inhibitor
Prior art date
Application number
AT06013455T
Other languages
English (en)
Inventor
Naoto Ono
Yasuhiro Funahashi
Taro Senba
Toshiaki Wakabayashi
Naoko Hata
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Application granted granted Critical
Publication of ATE412895T1 publication Critical patent/ATE412895T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT06013455T 2001-02-21 2002-02-21 Verfahren zur untersuchung der wirkung eines angiogenese-hemmers unter vermittlung durch hemmung der integrin-expression ATE412895T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001044646 2001-02-21

Publications (1)

Publication Number Publication Date
ATE412895T1 true ATE412895T1 (de) 2008-11-15

Family

ID=18906601

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06013455T ATE412895T1 (de) 2001-02-21 2002-02-21 Verfahren zur untersuchung der wirkung eines angiogenese-hemmers unter vermittlung durch hemmung der integrin-expression
AT02700679T ATE350660T1 (de) 2001-02-21 2002-02-21 Verfahren zur untersuchung der wirkung eines angionegesis-hemmers unter vermittlung durch hemmung der integrin-expression

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02700679T ATE350660T1 (de) 2001-02-21 2002-02-21 Verfahren zur untersuchung der wirkung eines angionegesis-hemmers unter vermittlung durch hemmung der integrin-expression

Country Status (11)

Country Link
US (1) US7122318B2 (de)
EP (2) EP1742052B1 (de)
JP (1) JP4255285B2 (de)
KR (1) KR20030080013A (de)
CN (2) CN100384482C (de)
AT (2) ATE412895T1 (de)
AU (1) AU2002233677B2 (de)
CA (1) CA2438427C (de)
DE (2) DE60229676D1 (de)
ES (2) ES2280502T3 (de)
WO (1) WO2002066073A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122318B2 (en) 2001-02-21 2006-10-17 Eisai Co., Ltd. Method for testing effect of angiogenesis inhibitor via integrin expression inhibition
JPWO2003022271A1 (ja) * 2001-09-05 2004-12-24 エーザイ株式会社 リンパ球活性化抑制剤および自己免疫疾患治療剤
WO2005090297A1 (en) * 2004-03-19 2005-09-29 Biotie Therapies Corporation Sulphonamide derivatives
WO2006090932A1 (ja) * 2005-02-28 2006-08-31 Eisai R & D Managemant Co., Ltd. スルホンアミド化合物の代理マーカー
PL2395004T3 (pl) 2005-06-22 2016-08-31 Plexxikon Inc Pochodne pirolo[2,3-b]pirydyny jako inhibitory kinazy białkowej
FI20055498A0 (fi) * 2005-09-16 2005-09-16 Biotie Therapies Corp Sulfonamidijohdannaisia
WO2007086605A1 (ja) * 2006-01-27 2007-08-02 Eisai R & D Management Co., Ltd. スルホンアミド化合物の効果を予測する方法
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
HUE070112T2 (hu) 2018-10-30 2025-05-28 Gilead Sciences Inc 3-(Kinolin-8-il)-1,4-dihidropirido[3,4-d]pirimidin-2,4-dion-származékok mint alpha4beta7 integrin gátlók gyulladásos betegségek kezelésére
JP7189369B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４β７インテグリンの阻害のための化合物
EP3873900B1 (de) 2018-10-30 2025-01-08 Gilead Sciences, Inc. Imidazo[1,2-a]pyridin-derivate als alpha4beta7 integrin-inhibitoren zur behandlung von entzündlichen erkrankungen
CN112996786B (zh) 2018-10-30 2024-08-20 吉利德科学公司 用于抑制α4β7整合素的化合物
JP7491996B2 (ja) 2019-08-14 2024-05-28 ギリアード サイエンシーズ， インコーポレイテッド α４β７インテグリンの阻害のための化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3545461B2 (ja) * 1993-09-10 2004-07-21 エーザイ株式会社 二環式ヘテロ環含有スルホンアミド誘導体
CN1221533C (zh) * 1993-09-10 2005-10-05 卫材株式会社 7－氨基－1h－吲哚衍生物
EP0889876B1 (de) * 1996-03-29 2001-07-25 G.D. SEARLE & CO. Meta-substituierte phenylsulphonamidderivate
CN1226172A (zh) * 1996-05-31 1999-08-18 斯克里普斯研究学院 用于抑制血管发生的方法和组合物
CA2286239A1 (en) * 1997-04-07 1998-10-15 Merck & Co., Inc. A method of treating cancer
US6096707A (en) * 1997-07-11 2000-08-01 Biotie Therapies Ltd. Integrin binding peptide and use thereof
US6291503B1 (en) * 1999-01-15 2001-09-18 Bayer Aktiengesellschaft β-phenylalanine derivatives as integrin antagonists
JP2000247949A (ja) 1999-02-26 2000-09-12 Eisai Co Ltd スルホンアミド含有インドール化合物
WO2001056607A1 (en) 2000-02-03 2001-08-09 Eisai Co., Ltd. Integrin expression inhibitors
US7122318B2 (en) 2001-02-21 2006-10-17 Eisai Co., Ltd. Method for testing effect of angiogenesis inhibitor via integrin expression inhibition

Also Published As

Publication number Publication date
DE60217300T2 (de) 2007-10-04
ES2280502T3 (es) 2007-09-16
HK1099363A1 (en) 2007-08-10
EP1362601B8 (de) 2007-02-28
AU2002233677B2 (en) 2005-01-06
EP1742052A1 (de) 2007-01-10
US7122318B2 (en) 2006-10-17
DE60217300D1 (de) 2007-02-15
WO2002066073A1 (en) 2002-08-29
CA2438427A1 (en) 2002-08-29
EP1362601B1 (de) 2007-01-03
DE60229676D1 (de) 2008-12-11
CN1620313A (zh) 2005-05-25
KR20030080013A (ko) 2003-10-10
EP1362601A4 (de) 2005-07-06
CN101025419A (zh) 2007-08-29
ATE350660T1 (de) 2007-01-15
CN100384482C (zh) 2008-04-30
JP4255285B2 (ja) 2009-04-15
US20040132783A1 (en) 2004-07-08
EP1362601A1 (de) 2003-11-19
CA2438427C (en) 2011-04-12
HK1059038A1 (en) 2004-06-18
ES2317368T3 (es) 2009-04-16
EP1742052B1 (de) 2008-10-29
JPWO2002066073A1 (ja) 2004-06-17

Similar Documents

Publication Publication Date Title
DE60229676D1 (de) Verfahren zur Untersuchung der Wirkung eines Angiogenese-Hemmers unter Vermittlung durch Hemmung der Integrin-Expression
DE60124736D1 (de) Vorrichtung zur messung des abschnittsweisen volumens und der elektrischen parallelleitfähigkeit einer herzkammer oder eines blutgefässes
ATE404890T1 (de) Verfahren und vorrichtung zur schnellen tomographischen messung der elektrischen leitfähigkeitsverteilung in einer probe
ATE539674T1 (de) Nichtinvasive blutanalyse durch optische sondierung der venen unter der zunge
BR0315287A (pt) Método para determinar a exatidão de um sensor de pressão em um cassete cirúrgico
ATE551950T1 (de) Verfahren zur messung von spannungszuständen eines materials und seine anwendung
BR0004251A (pt) Sistema e método de análise inteligente de equipamento elétrico cheio de fuido
ATE446561T1 (de) Sensoranordnung
DE60315151D1 (de) Diagnostischer test zur bestimmung der konzentration einer transienten proteolytischen aktivität in zusammengesetzten biologischen medien
Lawson et al. Tear strength of five elastomeric impression materials at two setting times and two tearing rates
DK1650348T3 (da) Fremgangsmåde til aftastning af et sporunderlag
DE60118797D1 (de) Verfahren zur detektion und messung der biomasse
ATE313788T1 (de) Feuchtigkeitsfühler mit kapazitivem feuchte- messelement und verfahren zur erfassung der luftfeuchtigkeit
DE60307448D1 (de) Vorrichtung und verfahren zur messung der vaskulären impedanz
ATE448496T1 (de) Verfahren und einrichtung zur hydrometeor- detektion
DE602004024484D1 (de) Vorrichtung und Verfahren zum Messen der Parameter bei Prüfungen während des Fluges eines Luftfahrzeug
ATE302947T1 (de) Verfahren zum nachweis eines lipoprotein- akutphaseprotein-komplexes
BRPI0415829A (pt) método para o teste ultra-sÈnico de um objeto, aparelho, e, uso do mesmo
DE60203524D1 (de) Verfahren zur messung des arteriolendrucks
ATE472427T1 (de) Verfahren zur messung eines drucks
ATE295797T1 (de) Verfahren zum erzeugen eines einen lagerschaden an einem achslager angebenden alarmsignals
DE602008006604D1 (de) Verfahren zur verarbeitung von spaltkammermesssignalen
ATE367575T1 (de) Verfahren und vorrichtung zur messung der bildsamkeit von materialien wie keramischen rohstoffen und massen
ATE535776T1 (de) Verfahren zur erkennung von dentalen oberflächenstrukturen
DE69918982D1 (de) Einrichtung zur herstellung von festen oder beweglichen zahnprothesen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1742052

Country of ref document: EP